Ollin Biosciences has announced important clinical trial results showing that OLN324, an investigational eye treatment, outperforms an existing therapy in treating two serious retinal diseases that threaten vision in millions…
Since its development and approval, Vabysmo has been a game-changer in the ophthalmologic space. The injectable VEGF and Ang-2 inhibitor treats diabetic macular edema (DME), macular edema with retinal vein…
Artificial intelligence (AI) is changing the way we live. It seems rare to find an industry where AI has not made at least a preliminary impact. In politics, AI-generated cartoons…
On February 7, 2022, Healthline reported that the FDA had approved Vabysmo (faricimab-svoa), an injectable therapy for those with wet age-relate macular degeneration (wAMD) and diabetic macular edema. This approval…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
